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Chronic Total Occlusion
Revascularization Is Alike
Recently, Valenti et al. (1) reported clinical and angiographic
outcomes after chronic total occlusion (CTO) revascularization
with drug-eluting stents (DESs). In this retrospective analysis, the
investigators demonstrated 77% procedural success with wire-based
CTO crossing strategies and concluded that although treatment
with DESs in this complex lesion subset is associated with favor-
able angiographic patency, CTO percutaneous coronary interven-
tion (PCI) involving subintimal tracking and luminal re-entry
(STAR) techniques was independently predictive of recurrent
occlusion. Speciﬁcally, among a small cohort of 54 patients,
recanalization was accomplished in 50 of them, yet ﬁnal Throm-
bolysis In Myocardial Infarction ﬂow grade 3 was achieved in only
34 patients (63%). At 1 year, a 57% reocclusion rate (31/54
attempts) was demonstrated, but only one-half of the STAR group
underwent angiographic follow-up. Reduced 3-year event-free
survival was also described in comparison with patients treated
with non-STAR techniques.
We believe that these ﬁndings represent misinterpretation in
what is considered subintimal dissection and re-entry CTO PCI
and may therefore be misleading regarding the advantages of the
current CTO PCI technique. First, the STAR technique is tradi-
tionally used as a bail-out maneuver for distal lumen entry through
creation of extensive subintimal dissection planes, often with the
unintended consequence of side branch loss. As exempliﬁed in this
and previous (2) studies, it is an unfavorable method associated
with low procedural and clinical success. Moreover, the long-term
success of this method is dependent on infrequent achievement of
ﬁnal TIMI ﬂow and preservation of distal vessel runoff that are
instead the objectives of more targeted re-entry techniques. For
these reasons, STAR is uncommonly performed at leading CTO
centers and should not be confused with more limited and
contemporary subintimal dissection and re-entry methods. Indeed,
it is likely that the majority of all successful CTO recanalizationprocedures involve guidewire advancement through the subintimal
vessel architecture, further confounding what deﬁnes subintimal
and nonsubintimal CTO PCI (3).
In summary, a predominantly antegrade wire-based strategy of
CTO-PCI is associated with low success rates. The STAR tech-
nique and related outcomes described by Valenti et al. (1) do not
represent more common (and contemporary) CTO PCI methods
that involve targeted guidewire re-entry. The expected adverse
outcome described in the present study should therefore not
discourage the application of more contemporary methods of
luminal re-entry that facilitate procedural success (4). More detailed
clinical outcomes speciﬁc to these methods will be reported from
the ongoing clinical study (NCT01435031).*David E. Kandzari, MD
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occlusions. Cathet Cardiovasc Interv 2012;80:807–13.ReplyWe thank Dr. Kandzari and colleagues for their interest in our
study (1). We do not believe that the STAR technique applied to
coronary vessels may be confused with the other techniques used in
chronic total occlusion (CTO) recanalization. The STAR tech-
nique is a relatively quick and easy technique to gain the distal
lumen of the vessel, but the re-entry into the true lumen of all main
branches may be difﬁcult, and even in these cases, the restoration
of a normal ﬂow is achieved in approximately half of cases (63% in
our study).
As stated in their letter, the STAR technique “is uncommonly
performed at leading CTO centers,” and this was the case at our
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2571center (STAR technique was used in only 5% of 1,035 CTO
patients). It is obvious that this technique cannot be confused with
other techniques of anterograde or retrograde CTO percutaneous
coronary intervention (PCI) that include intended limited dissec-
tion such as the CART, the reverse CART, or re-entry using the
BridgePoint device (BridgePoint Medical/Boston Scientiﬁc, Min-
neapolis, Minnesota).
The statement that in our study only one-half of the STAR
technique patients underwent angiographic follow-up is
misleading: angiography was performed in 28 of the 34 patients
with successful STAR technique (82% follow-up rate).
Your statement “In summary, a predominantly antegrade wire-
based strategy of CTO-PCI is associated with low success rates”
cannot be shared because the large majority of CTO PCIs are
performed using an anterograde approach, and the success rate in
a high-volume center is largely >80%.
Finally, we like to add that the main ﬁnding of the study was not
considered by Dr. Kandzari and colleagues: the everolimus-eluting
stent was associated with a dramatic decrease in the risk of reoc-
clusion compared with ﬁrst-generation drug-eluting stents (odds
ratio: 0.22). Dr. Kandzari and colleagues refer to an ongoing study
that will provide “more detailed clinical outcomes speciﬁc to these
methods” (NCT01435031): this study is a sponsored registry
(Abbott Vascular) that will include 250 patients over a period of 33
months, the aim of which is the assessment of the performance of
the sponsor devices (Xience stent, Progress wire, Mini-Trek
catheter) in CTO. The study design does not include angio-
graphic follow-up. We hope that with regard to the clinical
performance of the everolimus-eluting stent, the result of the study
will conﬁrm the results of our studies (1,2) despite the smaller
number of patients and the very long planned enrollment period.Renato Valenti, MD
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A Villain or a Decent Actor in the
Process of Ongoing Myocardial Injury?
In a recent issue of the Journal, Popp (1) reviewed the modern
techniques to measure cardiac troponin (cTn) and the value ofincreased cTn as a marker of myocardial injury and predictor of
future heart failure. More importantly, we have read and agree with
the author’s hypothesis: “cTn.to be an actor in this process of
ongoing myocardial injury and not simply a messenger of that
injury.” However, our next question is whether the actor is a villain
or decent.
Myocardial cell injuries that are caused by severe myocardial
ischemia can lead to the persistent release of cTn, which results in
a sustained increase in the peripheral circulation. During this
process, many types of cells, including cardiomyocytes and
immunocytes, are exposed to high concentrations of cTn in the
extracellular ﬂuid. Several studies have found that long-term
exposure of the immune system to cTn I can elicit an immune
response and produces anti-cTn antibodies, which in turn produce
serious cardiac inﬂammation and overt cardiac dysfunction (2,3).
However, we need to consider the direct effects of high-level cTn
on surrounding surviving cardiomyocytes after severe ischemia. Our
previous study demonstrated that during short-term myocardial
hypoxia/reoxygenation (48 h in total), the exogenous cTn I reduces
myocardial cell injuries and preserves the metabolic activity of
myocardial cells in vitro and that the protective effect is attributed
to the activity of cTn I and is dose dependent (4). Although the
underlying mechanisms of this protective effect are unclear, it
remains reasonable to propose the possibility that cTn has various
facets in the different stages during the process of myocardial
injury, just as heat shock protein-60, in the initial stages of stress, is
primarily responsible for maintaining the integrity of cellular
proteins, and is likely to induce autoimmune reactions to potentiate
the progressive process of atherosclerosis (5). At the beginning of
ischemia, a feedback response to the released cTn is initiated to
prevent further acute myocardial cell damage, but afterward, the
presence of anti-cTn autoantibodies is involved in the ongoing
myocardial damage. Accordingly, further studies are warranted to
see the true colors of cTn in the different stages during the ongoing
process of myocardial injury.Yong Peng, MD
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